Exploring the Effects of Genetic Variants and Inflammation on Vitamins Supplementation Treatment Outcomes in Epilepsy
NCT04488172 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200
Last updated 2020-07-27
Summary
The management of patients with epilepsy is focused on controlling seizures, avoiding treatment side effects, and restoring quality of life. However, about 30% of people are antiepileptic drugs (AEDs) resistance epilepsy after the adequate trials of two AEDs treatment. Genetic factors may contribute to the high interindividual variability in response or adverse effects (such as weight gain and altered lipid profiles) to AEDs. What's more, previous observational studies indicated that vitamin deficiency, such as vitamin B6, is common in patients with epilepsy due to epilepsy itself, AEDs use, or both. Therefore, investigators aim to (1) evaluate the impact of genetic variants on AED and multi-vitamins supplementation in epilepsy, and (2) establish the pharmacogenomics knowledge base of AED and multi-vitamins supplementation on clinical effectiveness in patients with epilepsy.
Conditions
Interventions
- DIETARY_SUPPLEMENT
-
Multi-vitamin supplementation
Vitamin B6:100 mg/day Vitamin B9: 5 mg/day Vitamin D: 1000 IU/day Vitamin E: 400 IU/day Co-Q10: 100 mg/day
Sponsors & Collaborators
-
National Cheng-Kung University Hospital
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-04-07
- Primary Completion
- 2021-07-31
- Completion
- 2021-07-31
Countries
- Taiwan
Study Locations
More Related Trials
-
Targeting the Gut to Improve Seizure Control in CDKL5 Deficiency Disorder (CDD)
NCT06448663 ·Status: RECRUITING ·Phase: NA
-
Efficacy Study of Folic Acid Supplementation in Adolescent Epileptics
NCT02318446 ·Status: UNKNOWN ·Phase: PHASE3
-
Exploration of Genotype Based Personalized Prescription of Valproate Sodium in Anti-epileptic Treatment
NCT01172626 ·Status: UNKNOWN
-
Association of Brain Derived Neurotrophic Factor (BDNF) rs6265 Gene Polymorphism With Susceptibility to Epilepsy
NCT05096871 ·Status: UNKNOWN
-
Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study
NCT00088452 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Predictors of Response to Anti Epilepsy in Epilepsy
NCT02883712 ·Status: TERMINATED
-
Efficacy of Omega-3 as Adjunctive Therapy for Medically Intractable Epilepsy: A Prospective Open-label Pilot Study
NCT02899741 ·Status: UNKNOWN ·Phase: PHASE2
-
Emotion/Behavior Problems, Neuropsychological Functioning, and Parental Adjustment in Children With Epilepsy
NCT00550940 ·Status: COMPLETED
-
Ketogenic Diet in Pediatric Intractable Epilepsy
NCT06310954 ·Status: RECRUITING ·Phase: NA
-
A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures
NCT00465517 ·Status: COMPLETED ·Phase: PHASE2
-
Medication Adherence in Individuals With Epilepsy
NCT01566500 ·Status: COMPLETED
-
Internet Administration of the Modified Atkins Diet for Adults With Intractable Epilepsy
NCT00436631 ·Status: COMPLETED ·Phase: PHASE3
-
Catamenial Epilepsy Treatment
NCT01299870 ·Status: UNKNOWN ·Phase: PHASE2
-
Drug Resistant Epilepsy: Clinical and Genetic Study
NCT04166305 ·Status: UNKNOWN
-
Effect of Valproic Acid Concentration on Photic Response
NCT00609245 ·Status: COMPLETED ·Phase: PHASE4
-
A Pilot Study of the Low Glycaemic Index Diet in Adults With Epilepsy
NCT03999827 ·Status: COMPLETED ·Phase: NA
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
NCT07222878 ·Status: COMPLETED ·Phase: PHASE1
-
Photosensitivity Proof of Concept Trial
NCT00894010 ·Status: COMPLETED ·Phase: PHASE2
-
Association Between Ferroptosis and Epilepsy
NCT05269901 ·Status: COMPLETED
-
Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy
NCT00232596 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures
NCT06769659 ·Status: RECRUITING ·Phase: PHASE2
-
An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy
NCT00210522 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.
NCT00425282 ·Status: COMPLETED ·Phase: PHASE3
-
Epigenetics and Gut Microbiota in Children With Epilepsy
NCT04063007 ·Status: UNKNOWN ·Phase: NA
-
Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy.
NCT00175864 ·Status: WITHDRAWN ·Phase: PHASE3